Search Site
Home >> Research Area >>Nature Products >> 18-Norabieta-8,11,13-trien-4-ol
18-Norabieta-8,11,13-trien-4-ol

18-Norabieta-8,11,13-trien-4-ol

Catalog No. BCN5064
Size Price Stock
20mg $298 In stock
Related Products

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris

Quality Control of 18-Norabieta-8,11,13-trien-4-ol

Chemical structure

18-Norabieta-8,11,13-trien-4-ol

Biological Activity of 18-Norabieta-8,11,13-trien-4-ol

1. 18-Norabieta-8,11,13-trien-4-ol exhibits significant antibacterial activity against gram (±) bacteria..

18-Norabieta-8,11,13-trien-4-ol Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

18-Norabieta-8,11,13-trien-4-ol Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Chemical Properties of 18-Norabieta-8,11,13-trien-4-ol

Cas No. 22478-65-5 SDF Download SDF
SMILES CC(C)c1ccc2c(c1)CC[C@@H]3[C@@]2(CCC[C@@]3(C)O)C
Standard InChIKey SOJWLJKPIIODOH-GUDVDZBRSA-N
Standard InChI InChI=1S/C19H28O/c1-13(2)14-6-8-16-15(12-14)7-9-17-18(16,3)10-5-11-19(17,4)20/h6,8,12-13,17,20H,5,7,9-11H2,1-4H3/t17-,18-,19-/m1/s1
Type of Compound Diterpenoids Appearance Powder
Formula C19H28O M.Wt 272.4
Solubility Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other courier with RT , or blue ice upon request.

Preparing Stock Solutions of 18-Norabieta-8,11,13-trien-4-ol

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 3.6711 mL 18.3554 mL 36.7107 mL 73.4214 mL 91.7768 mL
5 mM 0.7342 mL 3.6711 mL 7.3421 mL 14.6843 mL 18.3554 mL
10 mM 0.3671 mL 1.8355 mL 3.6711 mL 7.3421 mL 9.1777 mL
50 mM 0.0734 mL 0.3671 mL 0.7342 mL 1.4684 mL 1.8355 mL
100 mM 0.0367 mL 0.1836 mL 0.3671 mL 0.7342 mL 0.9178 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Preparation of 18-Norabieta-8,11,13-trien-4-ol

This product is isolated and purified from the herbs of Pinus yunnanensis

References on 18-Norabieta-8,11,13-trien-4-ol

Seventh International AFMBioMed Conference on AFM in Life Sciences and Medicine, April 11 to 15, 2016, Porto, Portugal.[Pubmed: 29024183]




European General Practice Research Network (EGPRN)Abstracts from the EGPRN conference in Riga, Latvia, 11?14 May 2017. Theme: 'Reducing the risk of chronic diseases in general practice/family medicine'.[Pubmed: 29022405]




The characteristics of coronary stenosis in 11,267 patients from Southwest China: a retrospective study.[Pubmed: 29019045]


The characteristics of coronary stenosis vary among the different countries or areas. 11,267 patients who have undergone coronary angiography (CAG) from three Southwest China hospitals were investigated. Patient characteristics, coronary stenosis and stent-implant information were recorded and analyzed according to two criteria: "visible stenosis" and "≥ 50% stenosis". The patients who have undergone CAG increased year by year, with patients from 60 to 69 years-old taking the highest ratio (34.69%). Based on the "≥ 50% stenosis" criteria, the stenotic frequency was 40.54% for Southwest China patients getting CAG. Only 8.14% patients suffered ≥ 3 stenotic vessels, while 11.58 and 20.82% patients had 2 or 1 stenotic vessel, respectively. However, when using the "visible stenosis" criteria, the stenotic frequency increased to 64.68%. The prevalence of stenosis increased with age based on the "visible stenosis" criteria. There were more male patients with stenosis than female except patients over 80 years old. The stenosis affected almost all main coronary arteries and their branches, with the most affected artery being the left anterior descending artery. There were 3246 cases (28.8%) implanted with 5423 stents with a concurrent age-dependent increasing tendency for stent-implant frequency and average implanted stent number. The numbers of patients who have undergone CAG and suffered from CVD increased rapidly. In these patients, positive rate of CAG was 64.67%, which increased to 72.2% in patients over 60-years old. The incidence of ≥ 75% stenosis and multiple stenosis increased with age, however it should be noticed there were 18.93% for ≥ 75% stenosis and 19.52% for multiple stenosis in patients under 40 years old.



Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma.[Pubmed: 29018077]




Kewords:

18-Norabieta-8,11,13-trien-4-ol ,22478-65-5,Nature Products, supplier, inhibitor,Antagonist,Blocker,Modulator,Agonist, activators, activates, potent, BioCrick

Online Inquiry

Fill out the information below

* Required Fields

CheckCode: